Patients are Sutro’s
passion and purpose.

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. 

Our Sutro Story

Science designed to deliver ENDLESS OPPORTUNITY

Enabling a future where more is POSSIBLE.

Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience.

Explore opportunities

Join us and thrive in a team that values diversity and collaboration.

INVESTOR RESOURCES

NASDAQ: STRO

Stock Symbol

Press Releases

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer – 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the...

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights – Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology – – Two new clinical trials,...

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference SOUTH SAN FRANCISCO, Calif., November 4, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company...